渲染靶标:SSR
Render Timestamp: 2025-01-08T18:53:41.976Z
Commit: f2d32940205a64f990b886d724ccee2c9935daff
XML generation date: 2024-09-30 01:57:27.538
Product last modified at: 2024-12-17T19:03:07.517Z
1% for the Planet 标识
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

LMO2 (E8K6I) Rabbit mAb #87182

Filter:
  • WB
  • IF
  • F
  • ChIP
Western Blotting Image 1: LMO2 (E8K6I) Rabbit mAb
Western blot analysis of extracts from TF-1, SET-2, and K-562 cells using LMO2 (E8K6I) Rabbit mAb.

To Purchase # 87182T

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa) 18
Source/Isotype Rabbit IgG
Application Key:
  • WB-Western Blotting 
  • IF-Immunofluorescence 
  • F-Flow Cytometry 
  • ChIP-Chromatin Immunoprecipitation 
Species Cross-Reactivity Key:
  • H-Human 
  • Related Products

Product Information

Product Usage Information

For optimal ChIP and ChIP-seq results, use 5 μL of antibody and 10 μg of chromatin (approximately 4 x 10^6 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.

Application Dilution
Western Blotting 1:1000
Immunofluorescence (Immunocytochemistry) 1:1600 - 1:6400
Flow Cytometry (Fixed/Permeabilized) 1:400 - 1:1600
Chromatin IP 1:100
Chromatin IP-seq 1:100

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

LMO2 (E8K6I) Rabbit mAb recognizes endogenous levels of total LMO2 protein. This antibody also recognizes a non-specific band of unknown origin at 78 kDa. Testing of LMO2 (E8K6I) Rabbit mAb with positive and negative models by Flow Cytometry and Immunofluorescence corroborated specificity of this antibody.

Species Reactivity:

Human

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human LMO2 protein.

Background

LIM-domain-only protein 2 (LMO2) is a transcriptional regulator that was first identified as a proto-oncogene activated by chromosomal translocations in T-cell acute lymphocytic leukemia (T-ALL) (1). Since then, LMO2 has been found to be a master regulator essential for erythroid development, as evidenced by homozygous LMO2 knockouts resulting in embryonic lethality in mice (2). LMO2 is an intrinsically unstructured protein that does not bind DNA directly, but rather acts as a scaffolding protein that recruits various transcription factors via its tandem cysteine-rich LIM domains to form a multi-protein DNA binding complex (3,4). The LMO2 complex plays a major role in hematopoiesis and was originally shown to consist of the transcription factors TAL1, E47, and GATA-1 in erythroid lineage cells, but variations of this complex may contain alternate transcription factors including LYL1, TAL2, GATA-2, and GATA-3 (5-9). The LMO2 complex also requires interaction with LIM-domain binding protein 1 (LDB1), which is necessary for LMO2 protein stability (10-11). In addition to hematopoietic tissue, LMO2 is also expressed in embryonic brain tissue, where it associates with BEX2 and the transcription factor NSCL-2 (12). Aberrant LMO2 expression is observed in several types of hematopoietic cancers, including large diffuse B-cell lymphoma (DLBCL), B-cell acute leukemia, (B-ALL), acute myeloid leukemia (AML), and T-ALL (13-16). LMO2-mediated T-ALL is primarily caused by the translocation t(11;14)(p13;q11) with the TCRD/A gene from chromosome 14q11, or the t(7;11)(q35;p13) translocation involving TCRB from 7q35 (1). In addition to hematopoietic cancers, overexpression of LMO2 in prostate stromal cells also facilitates prostate cancer progression by inducing expression of Interleukin-11 (IL-11), which stimulates STAT3 signaling in these cells (17).
  1. Boehm, T. et al. (1991) Proc Natl Acad Sci U S A 88, 4367-71.
  2. Warren, A.J. et al. (1994) Cell 78, 45-57.
  3. Chambers, J. and Rabbitts, T.H. (2015) Open Biol 5, 150062.
  4. Lécuyer, E. et al. (2007) J Biol Chem 282, 33649-58.
  5. Valge-Archer, V.E. et al. (1994) Proc Natl Acad Sci U S A 91, 8617-21.
  6. Wadman, I. et al. (1994) EMBO J 13, 4831-9.
  7. Wadman, I.A. et al. (1997) EMBO J 16, 3145-57.
  8. Osada, H. et al. (1995) Proc Natl Acad Sci U S A 92, 9585-9.
  9. Ono, Y. et al. (1998) Mol Cell Biol 18, 6939-50.
  10. Agulnick, A.D. et al. (1996) Nature 384, 270-2.
  11. Layer, J.H. et al. (2016) Mol Cell Biol 36, 488-506.
  12. Han, C. et al. (2005) Nucleic Acids Res 33, 6555-65.
  13. Natkunam, Y. et al. (2007) Blood 109, 1636-42.
  14. de Boer, J. et al. (2011) Leukemia 25, 321-30.
  15. Atay, M.H. et al. (2013) Histopathology 63, 293-4.
  16. Patel, J.L. et al. (2014) Histopathology 64, 226-33.
  17. Jiang, C.Y. et al. (2016) Oncotarget 7, 26247-58.
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
Alexa Fluor is a registered trademark of Life Technologies Corporation.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.